By Fineline Cube InnoCare Pharma Limited (HKG: 9969; SHA: 688428) announced that China’s National Medical Products Administration (NMPA) has approved the clinical trial application (CTA) for ICP‑B381, its self‑developed novel bispecific antibody‑drug conjugate (ADC) targeting PSMA and STEAP1, for the treatment of solid tumors including prostate cancer.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial application (CTA) authorization |
| Asset | ICP‑B381 — bispecific antibody‑drug conjugate (ADC) |
| Targets | PSMA and STEAP1 (dual‑targeting) |
| Indication | Solid tumors, including prostate cancer |
| Company | InnoCare Pharma Limited (HKG: 9969; SHA: 688428) |
| Announcement Date | 9 Sep 2026 |
| Next Steps | Initiation of first‑in‑human clinical trials (trial design and dosing schedule not disclosed) |
Drug Profile & Mechanism of Action
- Molecule: Novel bispecific antibody‑drug conjugate (ADC) — the first bispecific ADC developed on InnoCare’s proprietary ADC platform.
- Composition: A humanized anti‑PSMA/STEAP1 bispecific antibody conjugated with a next‑generation irreversible linker and a potent cytotoxic payload — both the linker and payload independently developed in‑house by the company.
- Targets: PSMA (prostate‑specific membrane antigen), highly overexpressed in prostate cancer, and STEAP1 (six‑transmembrane epithelial antigen of the prostate 1), abundantly expressed in prostate tumors with limited normal‑tissue expression.
- Innovation: Dual‑targeting of both PSMA and STEAP1 allows ICP‑B381 to effectively cover heterogeneous tumor cells and lower the risk of tumor escape — directly addressing antigen‑loss resistance, a recognized limitation of single‑target therapies in advanced prostate cancer.
- Intellectual Property: Fully self‑developed asset spanning the bispecific antibody, linker chemistry, and payload, establishing the technological foundation of InnoCare’s ADC platform for future conjugates.
Preclinical Evidence
| Evidence Area | Finding |
|---|---|
| Model | 22Rv1 human prostate cancer xenograft models — a standard preclinical system reflecting PSMA‑expressing, castration‑resistant disease biology |
| Antitumor Activity | Potent, dose‑dependent antitumor activity demonstrated |
| Quantitative Metrics | Not disclosed in the announcement |
| Safety / Toxicology Package | Not disclosed in the announcement |
The preclinical package supported the CTA submission to the NMPA, with dose‑dependent tumor suppression in the 22Rv1 model serving as the principal efficacy signal disclosed. Human pharmacokinetic, safety, and efficacy data remain to be generated in the forthcoming clinical program.
Market Impact & Outlook
- Solid‑Tumor Diversification: For InnoCare — best known for its BTK inhibitor franchise in lymphoma and autoimmune disease — ICP‑B381 marks a strategic expansion into solid‑tumor oncology through next‑generation modalities, combining two of the field’s most active design trends: ADCs and bispecific antibodies.
- Platform Validation: As the first bispecific ADC from InnoCare’s proprietary platform, the CTA clearance validates the company’s fully integrated, in‑house ADC engineering capability (antibody + linker + payload), positioning the platform for follow‑on assets rather than a single‑molecule bet.
- Competitive Landscape: Prostate cancer remains the most common non‑cutaneous malignancy in men worldwide, and metastatic castration‑resistant disease is still largely incurable. A dual‑target ADC offers mechanistic differentiation against single‑antigen ADCs and PSMA‑directed radioligand therapies by countering the intratumoral heterogeneity that drives antigen escape.
- Key Metrics to Watch: First‑patient‑in timing, Phase 1 dose‑escalation safety and pharmacokinetic readouts, early PSA response signals, and potential extension into other PSMA‑ or STEAP1‑expressing tumor types. Partnership or out‑licensing terms, if any, have not been disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical development plans, and commercial expectations for ICP‑B381. Actual results may differ due to risks including first‑in‑human safety and tolerability outcomes — a recognized hurdle that has constrained several ADC programs — clinical efficacy in heterogeneous tumor populations, and competitive dynamics in targeted prostate cancer therapy.-Fineline Info & Tech